SEARCH

SEARCH BY CITATION

Keywords:

  • bifidobacteria;
  • degranulation;
  • IgE-mediated allergy;
  • mast cells

ABSTRACT

  1. Top of page
  2. ABSTRACT
  3. ACKNOWLEDGMENTS
  4. REFERENCES

Sixteen heat-killed bifidobacteria isolated from human intestine and a probiotic strain Lactobacillus GG were tested for their ability to influence IgE-mediated degranulation of rat basophilic leukemia (RBL-2H3) cells in vitro. The bifidobacteria suppressed IgE-mediated degranulation of RBL-2H3 cells by 1.6–56.4% in a strain-dependent manner. Bifidobacteria from healthy infants expressed high inhibitory effects on IgE-mediated degranulation (41–55%), while those from allergic infants varied greatly in their effects against degranulation. Bifidobacteria taxonomically identified as Bifidobacterium bifidum exhibited much stronger inhibitory effects against IgE-mediated degranulation than those taxonomically identified as B. adolescentis (P < 0.05).These results indicate that the intestinal bifidobacteria might be one of factors influencing IgE-mediated allergic responses.

List of Abbreviations: 
ATCC

American type culture collection

B.

Bifidobacterium

CFU

colony forming units

Ig

immunoglobulin

IL

interleukin

LGG

Lactobacillus rhamnosus GG strain

MEM

Eagle's minimal essential medium

MRS

deMan Rogosa Sharpe

TMC

Takanashi microorganism collection

TNP

anti-2,4,6-trinitrophenyl

Bifidobacteria are one of the main groups of human intestinal microbiota which are predominant in infants (1). Low numbers of intestinal bifidobacteria have been reported to be an important aspect of aberrant intestinal microbiota in allergic infants (2–4), and these low numbers of Bifidobacterium have been detected even before the onset of allergy (2). In addition to these quantitative differences in Bifidobacterium microbiota, qualitative differences were also observed in our previous studies (5, 6). B. adolescentis and B. longum were the predominant bifidobacteria isolated from allergic infants, whereas the predominant bacteria isolated from age-matched healthy infants were B. infantis, B. bifidum, and B. breve. Recently, more scientific evidence has been reported which supports the findings that, in comparison to infants without allergy, infants with allergy in Western societies might be less frequently colonized with infant-type Bifidobacterium species, such as B. longum (biotype longum and infantis), B. bifidum and B. breve, and could be more frequently colonized by B. adolescentis and other species typical of the adult intestinal microbiota (7–10). Therefore, the composition of Bifidobacterium in infants is a prospective target in the management of allergic disease.

Mast cells and basophiles play an essential role in the pathogenesis of allergic reactions such as atopic dermatitis and asthma (11). Mast cells express a high-affinity Fc receptor for IgE and contain numerous mediator-filled granules. Antigen-induced cross-linkage of IgE bound to Fc receptors of mast cells causes the release of their granule content (degranulation) as well as the synthesis and secretion of other mediators, which leads to an immediate allergic reaction. Therefore, when developing anti-allergic pharmaceutical drugs, the emphasis should be on stabilization of mast cells and suppression of degranulation. Recently, some foods such as teas, fruit and vegetables have been proposed for alleviation of symptoms of allergic disease, because certain components of these foods can inhibit the activation of mast cells (12, 13). Furthermore, some non-pathogenic commensal and intestinal mucosa-associated bacteria have been found to function as strong direct inhibitors of mast cell degranulation (14–16).

In the present study, the rat basophilic leukemia mast cell line RBL-2H3 was used to test 16 strains of bifidobacteria isolated from human intestine and a probiotic strain, LGG, for their ability to suppress IgE-mediated degranulation of mast cells.

Sixteen strains of bifidobacteria, originally isolated from human intestine and stored at the Microbiological Laboratory of Takanashi Milk Products (Yokohama, Japan), were used (5). The probiotic strain, LGG (ATCC 53103), was supplied by Valio (Helsinki, Finland). Before use in experiments, bifidobacteria were cultured anaerobically using an Anaero Pack Kenki System (Mitsubishi Gas Chemical, Tokyo, Japan) in GAM broth (Nissui Seiyaku, Tokyo, Japan) at 37°C for 48 hr. Lactobacilli were routinely cultured at 37°C for 18 hr in MRS broth (Becton Dickinson, Sparks, MD, USA). After incubation, the bacteria were washed with sterilized saline, heat-killed at 100°C for 30 min, and lyophilized. Heat-inactivated bacteria were resuspended in tissue culture medium (see below) at a concentration of 100 μg/ml.

The RBL-2H3 cell line was purchased from ATCC (CRL-2256). The cells were cultured in Eagle's MEM (Wako, Osaka, Japan) supplemented with 10% heat-inactivated FBS (Gibco, Eggenstein, Germany), 2 mM L-glutamine, and 100 U/ml of penicillin.

The engagement of high-affinity IgE receptors (FcɛR1) on RBL-2H3 cells, which are known to express mast cell-specific molecules, initiates a number of biochemical events that eventually result in degranulation. The degranulation of RBL-2H3 cells was determined by measuring the release of β-hexosaminidase. The cells (3.0 × 105) were seeded in a 24-well plate and cultured overnight, then washed with PBS and cultured with or without bifidobacteria and lactobacilli (10 μg/ml) for 3 hr at 37°C in an atmosphere of air with 5% CO2. Next, the cells were washed twice with Eagle's MEM and stimulated with monoclonal TNP IgE (clone IgE-3) (40 ng/ml; BD Pharmingen, Tokyo, Japan). After being incubated for 2 hr at 37°C in an atmosphere of air with 5% CO2, the cells were washed once with Tyrode buffer (126 mM NaCl, 5.6 mM glucose, 4.0 mM KCl, 0.6 mM KH2PO4, 10.0 mM HEPES, 0.6 mM MgCl2/6H2O, 1.0 mM CaCl2, and 0.1% BSA; pH 7.4) and then stimulated with TNP-BSA (3 ng/ml) for 1 hr at 37°C. The supernatants were transferred to a 96-well microplate and 0.2% Triton X-100 added to the cells, which were then incubated with 1.3 mg/ml of p-nitrophenyl-N-acetyl-β-D-glucopyranoside (Nakarai, Kyoto, Japan) in 0.1 M sodium citrate buffer (pH 4.5) for 40 min at 37°C. After adding a stop solution (0.2 M glycine; pH 11.0), the optical density at 450 nm was measured using a microplate reader (ImmunoMin NJ-2300; InterMed, Osaka, Japan). The total β-hexosaminidase content was determined by cell lysis with 0.1% Triton-X 100. Inhibition (%) of the release of β-hexosaminidase in the test sample was calculated using the following equation:   Inhibition (%) = 100 −[(T/A)/(C/A) × 100]      [1]   in which C (control) is antigen-induced β-hexosaminidase release in the absence of Bifidobacterium or Lactobacillus[TNP-BSA(+) − TNP-BSA(−)], T is the antigen-induced β-hexosaminidase of the test sample [TNP-BSA(+) − TNP-BSA(−)], and A is the total β-hexosaminidase content (Triton X-100 extract).

The results were expressed as mean ± SD (n= 3). The statistical significance of differences between the two groups was calculated using the unpaired Student's t-test or Welch's t-test after an F-test.

IgE-mediated degranulation by RBL-2H3 cells was measured by analyzing β-hexosaminidase in the culture supernatant. LGG inhibited IgE-mediated degranulation of RBL-2H3 cells by 50.3%. The 16 tested bifidobacteria suppressed IgE-mediated degranulation by 1.6–57.7%, each bacterium having its own characteristic inhibitory effect on IgE-mediated degranulation of RBL-2H3 (Table 1). Of the tested bifidobacteria, B. bifidum TMC3116 from healthy infants expressed the strongest inhibitory effect (57.7%) on IgE-mediated degranulation of RBL-2H3 cells, whereas B. adolescentis TMC2737 from allergic infants suppressed degranulation by only 13.6%. The bifidobacteria originally isolated from healthy infants suppressed IgE-mediated degranulation more than those isolated from allergic infants, although the difference was not statistically significant (P= 0.25). On the other hand, bacteria taxonomically identified as B. bifidum significantly suppressed IgE-mediated degranulation of RBL-2H3 cells more than those taxonomically identified as B. adolescentis (Fig. 1) (P < 0.05).

Table 1.  Rates of inhibition of ß-hexosaminidase release by the bifidobacteria and lactobacillus tested in this study
Species NameStrain No.OriginInhibition rate (%)
B. adolescentisTMC 2701Healthy adult 1.62 ± 13.85
B. adolescentisTMC 2704Healthy adult20.15 ± 1.77
B. adolescentisTMC 2705Healthy adult33.62 ± 3.17
B. adolescentisTMC 2710Healthy adult26.80 ± 28.46
B. adolescentisTMC 2718Allergic infant31.25 ± 15.29
B. adolescentisTMC 2720Allergic infant53.85 ± 3.19
B. adolescentisTMC 2736Allergic infant56.43 ± 3.82
B. adolescentisTMC 2737Allergic infant13.55 ± 4.53
B. adolescentisTMC 2738Allergic infant47.89 ± 6.13
B. adolescentisTMC 2739Allergic infant24.60 ± 18.73
B. bifidumTMC 3103Dairy food41.77 ± 11.76
B. bifidumTMC 3108Healthy infant55.70 ± 3.72
B. bifidumTMC 3110Healthy infant42.13 ± 3.53
B. bifidumTMC 3111Healthy infant55.71 ± 4.51
B. bifidumTMC 3115Healthy infant41.30 ± 16.34
B. bifidumTMC 3116Healthy infant57.71 ± 2.59
L.rhamnosusGGHuman intestine50.34 ± 3.14
image

Figure 1. Comparison of inhibitory effect of B. adolescentis and B. bifidum on β-hexosaminidase release. RBL-2H3 cells were preincubated with bifidobacteria for 3 hr prior to IgE sensitization. After stimulation with antigen, degranulation was determined by measuring the release of β-hexosaminidase. The inhibition rates of each of the ten B. adolescentis strains and six B. bifidum strains shown in Table 1 are represented by open circles and the overall inhibition rates for each group are expressed as means ± SD. *, difference between B. adolescentis and B. bifidum group is significant (P < 0.05).

Download figure to PowerPoint

RBL-2H3 is a well-established cell line used as a model of mast cells and the release of β-hexosaminidase is a well-established indicator of IgE-mediated degranulation. RBL-2H3 cells have been widely used as a test model to evaluate the potent anti-allergic effects of flavonoids, peptides and other food ingredients, and environmental components through their property of suppressing IgE-mediated degranulation of these cells (17). In the present study, the human intestinal bifidobacteria used were examined for their ability to activate mast cells using RBL-2H3 cells. Each of the tested bifidobacteria expressed its characteristic inhibitory effect against IgE-mediated degranulation in RBL-2H3 cells in a strain-dependent manner. Compared with the infant-type species B. bifidum, of all the tested strains which strongly inhibited degranulation the adult-type species B. adolescentis showed the greatest diversity in its ability to affect IgE-mediated degranulation. B. adolescentis strains such as TMC2701 and TMC2704 from healthy adults and TMC2737 from allergic infants showed relatively reduced ability to suppress degranulation compared with strains of B. bifidum. These results are in good agreement with those of our previous study in which strains of B. adolescentis differed from those of B. bifidum with resect to their immune modulatory effects (5, 18). To our knowledge, the present study is the first to indicate that different bifidobacteria influence IgE-mediated degranulation of mast cells differently, infant-type bifidobacteria such as B. bifidum having a greater influence on IgE-mediated allergic inflammation than other species such as B. adolescentis.

LGG has been shown to reduce the clinical symptoms of atopic eczema in breast-feeding infants whose mothers are given LGG, and in milk-hypersensitive infants who consume a hydrolyzed whey formula supplemented with LGG. A 7-year clinical follow-up study has shown that this probiotic bacterium is effective in protecting infants with a genetically high risk of allergic disease from the development of atopic disease (19, 20). In other well-designed clinical studies, LGG improved atopic eczema/dermatitis, stimulation of interferon-γ production being suggested as one of the possible mechanisms for this bacterium's health-promoting effects (21, 22). In another recent study, fermented milk prepared with LGG was found to improve the allergic symptoms of Japanese cedar pollinosis (23). However, LGG did not modulate serum IgE synthesis in these allergic subjects, although it has been found to slightly affect serum IgE concentrations in ovalbumin-sensitized mice (24). On other hand, in NC/Nga mice, a model of human atopic dermatitis, ingestion of heat-treated LGG inhibited the onset and development of atopic skin lesions, and this effect was accompanied by reduced degranulation and infiltration of mast cells and eosinophils (25). These results suggest that another underlying mechanism by which LGG exerts its health-promoting effects in allergic patients could be via a direct influence on mast cells. In the present study, the observation that some bifidobacteria from healthy infants affect mast cells in the same way as LGG does suggests that these bifidobacteria possess similar health promoting effects in allergic subjects as those observed in LGG related studies.

In order to clarify the underlying mechanisms by which tested bacteria expressed inhibitory effects against IgE-mediated degranulation of mast cells, LGG was tested for its abilities to influence IgE binding to FcɛRI, activate expression of an intracellular signaling cascade, and stimulate secretion of cytokines such as TNF-α from RBL-2H3 cells. Some slight effects were observed, leaving the mechanisms by which LGG affects mast cells unclear.

ACKNOWLEDGMENTS

  1. Top of page
  2. ABSTRACT
  3. ACKNOWLEDGMENTS
  4. REFERENCES

We thank Kazumi Kasakura for conducting the β-hexosaminidase release assay. This study was supported by a Grant-in-Aid for Research and Development from the Japanese Ministry of Agriculture and Forestry.

REFERENCES

  1. Top of page
  2. ABSTRACT
  3. ACKNOWLEDGMENTS
  4. REFERENCES
  • 1
    Mitsuoka T. (1984) Taxonomy and ecology of bifidobacteria. Bifidobacteria Microflora 3: 1128.
  • 2
    Björkstén B., Naaber P., Sepp E., Mikelsaar M. (1999) The intestinal microflora in allergic Estonian and Swedish 2-year-old children. Clin Exp Allergy 29: 3426.
  • 3
    Kalliomäki M., Kirjavainen P., Eerola E., Kero P., Salminen S., Isolauri E. (2001) Distinct patterns of neonatal gut microflora in infants developing or not developing atopy. J Allergy Clin Immunol 107: 12934.
  • 4
    Sepp E., Julge K., Mikelsaar M., Bjorksten B. (2005) Intestinal microbiota and immunoglobulin E responses in 5-year-old Estonian children. Clin Exp Allergy 35: 11416.
  • 5
    He F., Ouwehand A.C., Isolauri E., Hashimoto H., Benno Y., Salminen S. (2001) Comparison of mucosal adhesion and species identification of bifidobacteria isolated from healthy and allergic infants. FEMS Immunol Med Microbiol 30: 434.
  • 6
    Ouwehand A.C., Isolauri E., He F., Hashimoto H., Benno Y., Salminen S. (2001) Differences in Bifidobacterium flora composition in allergic and healthy infants. J Allergy Clin Immunol 108: 1445.
  • 7
    Suzuki S., Shimojo N., Tajiri Y., Kumemura M., Kohno Y. (2007). Differences in the composition of intestinal Bifidobacterium species and the development of allergic diseases in infants in rural Japan. Clin Exp Allergy 37: 50611.
  • 8
    Stsepetova J., Sepp E., Julge K., Vaughan E. Mikelsaar M., De Vos W.M. (2007) Molecularly assessed shifts of Bifidobacterium ssp. and less diverse microbial communities are characteristic of 5-year-old allergic children. FEMS Immunol Med Microbiol 51: 2609.
  • 9
    Gore C., Munro K., Lay C., Bibiloni R., Morris J., Woodcock A., Custovic A., Tannock G.W. (2008) Bifidobacterium pseudocatenulatum is associated with atopic eczema: a nested case-control study investigating the fecal microbiota of infants. J Allergy Clin Immunol 121: 13540.
  • 10
    Lahtinen S.J., Boyle R.J., Kivivuori S., Oppedisano F., Smith K.R., Robins-Browne R., Salminen S.J., Tang, M.L. (2009) Prenatal probiotic administration can influence Bifidobacterium microbiota development in infants at high risk of allergy. J Allergy Clin Immunol 123: 499501.
  • 11
    Abbas A.K. Lichtman A.H. (2001) Basic Immunology: Functions and Disorders of the Immune System. Philadelphia , Pennsylvania , USA : W.B. Saunders Company.
  • 12
    Kobayashi S., Tanabe S. (2006). Evaluation of the anti-allergic activity of Citrus unshiu using rat basophilic leukemia RBL-2H3 cells as well as basophils of patients with seasonal allergic rhinitis to pollen. Int J Mol Med 17: 5115.
  • 13
    Kanda T., Akiyama H., Yanagida A., Tanabe M., Goda Y., Toyoda M., Teshima R., Saito Y. (1998) Inhibitory effects of apple polyphenol on induced histamine release from RBL-2H3 cells and rat mast cells. Biosci Biotechnol Biochem 62: 12849.
  • 14
    Chen X., Feng B.S., Zheng P.Y., Liao X.Q., Chong J., Tang S.G., Yang P.C. (2008) Fc gamma receptor signaling in mast cells links microbial stimulation to mucosal immune inflammation in the intestine. Am J Pathol 73: 164756.
  • 15
    Magerl M., Lammel V., Siebenhaar F., Zuberbier T., Metz M., Maurer M. (2008) Non-pathogenic commensal Escherichia coli bacteria can inhibit degranulation of mast cells. Exp Dermatol 17: 42735.
  • 16
    Krämer S., Sellge G., Lorentz A., Krueger D., Schemann M., Feilhauer K., Gunzer F., Bischoff, S.C. (2008) Selective activation of human intestinal mast cells by Escherichia coli hemolysin. J Immunol 181: 143845.
  • 17
    Morimoto Y., Yasuhara T., Sugimoto A., Inoue A., Hide I., Akiyama M., Nakata Y. (2003) Anti-allergic substances contained in the pollen of Cryptomeria japonica possess diverse effects on the degranulation of RBL-2H3 cells. J Pharmacol Sci 92: 2915.
  • 18
    He F., Morita H., Ouwehand A.C., Hosoda M., Hiramatsu M., Kurisaki J., Isolauri E., Benno Y., Salminen S. (2002) Stimulation of the secretion of pro-inflammatory cytokines by Bifidobacterium strains. Microbiol Immunol 46: 7815.
  • 19
    Kalliomäki M., Salminen S., Arvilommi H., Kero P., Koskinen P., Isolauri E. (2001) Probiotics in primary prevention of atopic disease: a randomized placebo-controlled trial. Lancet 357: 10769.
  • 20
    Kalliomäki M., Salminen S., Poussa T., Arvilommi H., Isolauri E. (2003) Probiotics and prevention of atopic disease: 4-year follow-up of a randomized placebo-controlled trial. Lancet 361: 186971.
  • 21
    Viljanen M., Savilahti E., Haahtela T., Juntunen-Backman K., Korpela R., Poussa T., Tuure T., Kuitunen M. (2005) Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy 60: 494500.
  • 22
    Viljanen M., Kuitunen M., Haahtela T., Juntunen-Backman K., Korpela R., Savilahti E. (2005) Probiotic effects on faecal inflammatory markers and on faecal IgA in food allergic atopic eczema/dermatitis syndrome infants. Pediatric Allergy Immunol 16: 6571.
  • 23
    Kawase M., He F., Kubota A., Harata G., Hiramatsu M. (2007) Orally administrated Lactobacillus gasseri TMC0356 and Lactobacillus GG alleviated nasal blockage of guinea pig with allergic rhinitis. Microbiol Immunol 51: 110914.
  • 24
    Kawase M., He F., Harata G., Kubota A., Mizumachi K., Hiramatsu M. (2007) Characterization of inhibitory effects of Lactobacilli against immunoglobulin E production in vitro and in vivo. Int J Probiotics Prebiotics 2: 2938.
  • 25
    Sawada J., Morita H., Tanaka A., Saminen S., He F., Matsuda H. (2006) Ingestion of heat-treated Lactobacillus rhamnosus GG prevents development of atopic dermatitis in NC/Nga mice. Clin Exp Allergy 37: 296303.